Reimbursement Review Reports
( Last Updated : October 5, 2022)
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| (TBC) | risankizumab | Crohn's disease | Pending | |||
| Abecma | idecabtagene vicleucel | Multiple myeloma | Do not reimburse | Complete | ||
| Abilify | Aripiprazole | Schizophrenia and related psychotic disorders | List with clinical criteria and/or conditions | Complete | ||
| Abilify | Aripiprazole | Depression, Major Depressive Disorder | Do not list | Complete | ||
| Abilify | Aripiprazole | Schizophrenia | Do not list | Complete | ||
| Abilify Maintena | Aripiprazole | Schizophrenia | List with criteria/condition | Complete | ||
| Abraxane | Nab-paclitaxel | Metastatic Pancreatic Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Abstral | Fentanyl citrate | Pain, breakthrough cancer pain | Do not list | Complete | ||
| Aclasta | Zoledronic acid | Osteoporosis, postmenopausal women | Do not list | Complete | ||
| Aclasta | Zoledronic acid | Osteoporosis | List with clinical criteria and/or conditions | Complete |